TY - JOUR
T1 - An ecological study on reinfection rates using a large dataset of RT-qPCR tests for SARS-CoV-2 in Santiago of Chile
AU - Acuña-Castillo, Claudio
AU - Barrera-Avalos, Carlos
AU - Bachelet, Vivienne C.
AU - Milla, Luis A.
AU - Inostroza-Molina, Ailén
AU - Vidal, Mabel
AU - Luraschi, Roberto
AU - Vallejos-Vidal, Eva
AU - Mella-Torres, Andrea
AU - Valdés, Daniel
AU - Reyes-López, Felipe E.
AU - Imarai, Mónica
AU - Rojas, Patricio
AU - Sandino, Ana María
N1 - Publisher Copyright:
Copyright © 2023 Acuña-Castillo, Barrera-Avalos, Bachelet, Milla, Inostroza-Molina, Vidal, Luraschi, Vallejos-Vidal, Mella-Torres, Valdés, Reyes-López, Imarai, Rojas and Sandino.
PY - 2023
Y1 - 2023
N2 - Introduction: As the SARS-CoV-2 continues to evolve, new variants pose a significant threat by potentially overriding the immunity conferred by vaccination and natural infection. This scenario can lead to an upswing in reinfections, amplified baseline epidemic activity, and localized outbreaks. In various global regions, estimates of breakthrough cases associated with the currently circulating viral variants, such as Omicron, have been reported. Nonetheless, specific data on the reinfection rate in Chile still needs to be included. Methods: Our study has focused on estimating COVID-19 reinfections per wave based on a sample of 578,670 RT-qPCR tests conducted at the University of Santiago of Chile (USACH) from April 2020 to July 2022, encompassing 345,997 individuals. Results: The analysis reveals that the highest rate of reinfections transpired during the fourth and fifth COVID-19 waves, primarily driven by the Omicron variant. These findings hold despite 80% of the Chilean population receiving complete vaccination under the primary scheme and 60% receiving at least one booster dose. On average, the interval between initial infection and reinfection was found to be 372 days. Interestingly, reinfection incidence was higher in women aged between 30 and 55. Additionally, the viral load during the second infection episode was lower, likely attributed to Chile's high vaccination rate. Discussion: This study demonstrates that the Omicron variant is behind Chile's highest number of reinfection cases, underscoring its potential for immune evasion. This vital epidemiological information contributes to developing and implementing effective public health policies.
AB - Introduction: As the SARS-CoV-2 continues to evolve, new variants pose a significant threat by potentially overriding the immunity conferred by vaccination and natural infection. This scenario can lead to an upswing in reinfections, amplified baseline epidemic activity, and localized outbreaks. In various global regions, estimates of breakthrough cases associated with the currently circulating viral variants, such as Omicron, have been reported. Nonetheless, specific data on the reinfection rate in Chile still needs to be included. Methods: Our study has focused on estimating COVID-19 reinfections per wave based on a sample of 578,670 RT-qPCR tests conducted at the University of Santiago of Chile (USACH) from April 2020 to July 2022, encompassing 345,997 individuals. Results: The analysis reveals that the highest rate of reinfections transpired during the fourth and fifth COVID-19 waves, primarily driven by the Omicron variant. These findings hold despite 80% of the Chilean population receiving complete vaccination under the primary scheme and 60% receiving at least one booster dose. On average, the interval between initial infection and reinfection was found to be 372 days. Interestingly, reinfection incidence was higher in women aged between 30 and 55. Additionally, the viral load during the second infection episode was lower, likely attributed to Chile's high vaccination rate. Discussion: This study demonstrates that the Omicron variant is behind Chile's highest number of reinfection cases, underscoring its potential for immune evasion. This vital epidemiological information contributes to developing and implementing effective public health policies.
KW - COVID-19 pandemic
KW - reinfection
KW - SARS-CoV-2
KW - vaccines
KW - variants of concern
UR - http://www.scopus.com/inward/record.url?scp=85165609803&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2023.1191377
DO - 10.3389/fpubh.2023.1191377
M3 - Article
C2 - 37492136
AN - SCOPUS:85165609803
SN - 2296-2565
VL - 11
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 1191377
ER -